NOW AVAILABLE ON DEMAND
MEET THE PANEL
Cell and gene therapies have had tremendous effects on the treatment of previously incurable diseases. Many products are already on the road to commercialization.
However, scaling complex manufacturing operations is still a challenge and managing multiple concurrent workstreams is onerous and very manual. Each therapeutic developer needs to manage multiple factors/resources internally and externally to deliver a great customer and patient experience.
Join us as a panel of experts discusses key challenges in industrial manufacturing, supply chain management, patient operations and order fulfilment. The panel of industry leaders will also share insights from their own experiences.
WHAT TO EXPECT
This 60-minute session will feature a short presentation with a session dedicated to an interactive panel discussion where you will be able to ask your questions.
Part 1: The panel addresses key challenges associated with scheduling and forecast allocation for advanced therapies, including:
- Current state of industrial standard: how do companies manage complex internal and external operations?
- Scheduling: what are the key challenges and processes for scheduling and re-scheduling batch manufacturing?
- Slot allocation: minimizing impact on planned activities and how to manage exceptions/conflicts
- Connected processes: challenges in managing a process that requires technical ops, QC, QA, facilities and other teams to be in-sync for manufacturing and releasing each batch
- Optimization: how can we optimize this complex process? What lessons have the panel learnt?
Part 2: The panel answers audience questions with an interactive Q&A.
MEET THE PANEL
David Kim
Head of Supply Chain
Arcellx
Andrew Case
Head of Supply Chain
Roche
Ian Gaudet
Senior Director, Site Head
Miltenyi Biotec
Albert Ribickas
Manager, Blood and Marrow Transplant Laboratory/Clinical Trial and Commercial Product Handling Team
Moffitt Cancer Center
Stefanie Leysen
CGT Solution Manager
BINOCS
Moderator: Ryan Leahy
Vice President of Research
Phacilitate
This content is brought to you in partnership with Phacilitate and BINOCS who are independent but joint controllers. You may receive follow up communications from Phacilitate and BINOCS with information directly related to this content, and you will be able to opt out from being contacted by using the unsubscribe links in these emails.